There will be a greater need for adaptable regulatory pathways as personalized medicine becomes more popular & new technologies like gene editing & artificial intelligence appear. This change may force regulatory bodies to reevaluate how they allot IND slots, possibly making them more accessible or changing the requirall game chartements for approval. Such modifications may facilitate quicker access to cutting-edge treatments that meet urgent medical needs. Moreover, the significance of effective drug development procedures will only increase as long as there are global health issues, as demonstrated by the most recent pandemics. In order to ensure that novel treatments can be developed quickly while upholding strict safety standards, IND slots will play a critical role. Pharmaceutical businesses will need to continue being flexible and sensitive to the needs of the market as well as the expectations of regulators as they adjust to these shifting dynamics.